advertisement
Abstract #6515 Published in IGR 3-2
Topical verapamil in glaucoma filtration surgery
Shin DH; Kardasis CT; Kim C; Juzych MS; Hughes BA; Keole NSJournal of Glaucoma 2001; 10: 211-214
PURPOSE: Because of the reported antifibroblastic effect of verapamil, a calcium-channel blocker, the authors investigated the potential benefit of adjunctive topical verapamil in patients undergoing glaucoma filtration surgery. METHODS: This prospective, double-masked, randomized study included 56 eyes of 56 consecutive patients with chronic open-angle glaucoma undergoing trabeculectomy (primary or surgical revision of failed trabeculectomy), trabeculectomy combined with cataract surgery, or Molteno drainage device implantation. Postoperatively, the treated eyes received verapamil (0.25%) or one drop of placebo four times a day for one month in addition to 1% prednisolone four times a day and corticosteroid-antibiotic ophthalmic ointment at bedtime. RESULTS: There were no significant differences in preoperative mean intraocular pressure (IOP), mean number of medications, and glaucoma severity between the verapamil and placebo groups. Neither were there significant differences between the two groups regarding filtration success rate, mean IOP, and mean number of medications on postoperative days 1,4, or 7, and at postoperative months 1, 2, 3, 4, 5, and 6 (p > 0.05). CONCLUSION: There was no significant benefit from adjunctive topical verapamil when it was used after trabeculectomy, trabeculectomy combined with cataract surgery, or Molteno drainage device implantation.
Dr D.H. Shin, Kresge Eye Institute, Wayne State University School of Medicine, 4717 St Antoine Boulevard, Detroit, MI 48201-1423, USA. dongshin@med.wayne.edu
Classification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
